Consistent with other Mdm2 inhibitors, delayed thrombocytopenia, neutropenia, anemia, and gastrointestinal side effects were observed in patients with hematologic malignancies, though these effects were not seen in solid tumor patients, suggesting a treatment-related cause [73,74]. Here, MDM2 is linked to Thrombocytopenia.